EX-99.1

Exhibit 99.1

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—UNITED STATES

(Unaudited; Amounts in millions)


	A		B			C		D			E		F			G			H			I=A+B+C+D +E+F+G+H
	BDX as Reported		BD Realign BUs			Bard as Reported		Bard Realign BUs			Bard Align Region Reporting		Divestiture Adjust			Gore Royalty Classification Adjust			Interco Adjust			Total NewCo as Adjusted
			FN#1			FN#2		FN#3			FN#4		FN#5			FN#6			FN#7
12 Months Ended September 30, 2016
BD MEDICAL
Medication Delivery Solutions (previously Medication and Procedural Solutions)		1,959		(599	)		—		556			1		(19	)		—			(14	)		1,883
Medication Management Solutions		1,779		—			—		—			—		—			—			—			1,779
Diabetes Care		521		—			—		—			—		—			—			—			521
Pharmaceutical Systems		328		—			—		—			—		—			—			—			328
Respiratory Solutions		559		—			—		—			—		(559	)		—			—			—

TOTAL		5,144		(599	)		—		556			1		(578	)		—			(14	)		4,510

BD LIFE SCIENCES
Preanalytical Systems		715		—			—		—			—		—			—			—			715
Diagnostic Systems		600		—			—		—			—		—			—			—			600
Biosciences		433		—			—		—			—		—			—			—			433

TOTAL		1,748		—			—		—			—		—			—			—			1,748

BD INTERVENTIONAL
Surgery		—		585			—		498			2		(37	)		—			—			1,047
Peripheral Intervention		—		14			—		822			3		—			(158	)		—			682
Urology and Critical Care		—		—			—		635			1		—			—			—			635
Legacy Bard Product Groups
Vascular		—		—			637		(637	)		—		—			—			—			—
Urology		—		—			636		(636	)		—		—			—			—			—
Oncology		—		—			691		(691	)		—		—			—			—			—
Surgical Specialties		—		—			480		(480	)		—		—			—			—			—
Other		—		—			67		(67	)		—		—			—			—			—

TOTAL		—		599			2,511		(556	)		5		(37	)		(158	)		—			2,364

TOTAL UNITED STATES		6,893		—			2,511		—			6		(615	)		(158	)		(14	)		8,622

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously Medication and Procedural Solutions) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 1

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—UNITED STATES

(Unaudited; Amounts in millions)


	A		B			C		D			E		F			G			H			I=A+B+C+D +E+F+G+H		J		K=(I-J)/J
	BDX as Reported		BD Realign BUs			Bard as Reported		Bard Realign BUs			Bard Align Region Reporting		Divestiture Adjust			Gore Royalty Classification Adjust			Interco Adjust			Total NewCo as Adjusted		PY Comparable Period		Reported % Change
			FN#1			FN#2		FN#3			FN#4		FN#5			FN#6			FN#7
12 Months Ended September 30, 2017
BD MEDICAL
Medication Delivery Solutions (previously Medication and Procedural Solutions)		1,968		(591	)		—		571			1		—			—			(14	)		1,935		1,883		2.8%
Medication Management Solutions		1,843		—			—		—			—		—			—			—			1,843		1,779		3.6%
Diabetes Care		546		—			—		—			—		—			—			—			546		521		4.9%
Pharmaceutical Systems		328		—			—		—			—		—			—			—			328		328		0.1%
Respiratory Solutions		—		—			—		—			—		—			—			—			—		—		NM

TOTAL		4,685		(591	)		—		571			1		—			—			(14	)		4,652		4,510		3.2%

BD LIFE SCIENCES
Preanalytical Systems		741		—			—		—			—		—			—			—			741		715		3.7%
Diagnostic Systems		622		—			—		—			—		—			—			—			622		600		3.7%
Biosciences		455		—			—		—			—		—			—			—			455		433		4.9%

TOTAL		1,818		—			—		—			—		—			—			—			1,818		1,748		4.0%

BD INTERVENTIONAL
Surgery		—		577			—		511			2		(39	)		—			—			1,051		1,047		0.4%
Peripheral Intervention		—		14			—		875			3		—			(173	)		—			718		682		5.4%
Urology and Critical Care		—		—			—		681			—		—			—			—			681		635		7.2%
Legacy Bard Product Groups
Vascular		—		—			687		(687	)		—		—			—			—			—		—
Urology		—		—			676		(676	)		—		—			—			—			—		—
Oncology		—		—			714		(714	)		—		—			—			—			—		—
Surgical Specialties		—		—			491		(491	)		—		—			—			—			—		—
Other		—		—			71		(71	)		—		—			—			—			—		—

TOTAL		—		591			2,638		(571	)		5		(39	)		(173	)		—			2,451		2,364		3.7%

TOTAL UNITED STATES		6,504		—			2,638		—			6		(39	)		(173	)		(14	)		8,921		8,622		3.5%

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 2

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL

(Unaudited; Amounts in millions)


	A		B			C		D			E			F			G		H		I=A+B+C+D +E+F+G+H
	BDX as Reported		BD Realign BUs			Bard as Reported		Bard Realign BUs			Bard Align Region Reporting			Divestiture Adjust			Gore Royalty Classification Adjust		Interco Adjust		Total NewCo as Adjusted
			FN#1			FN#2		FN#3			FN#4			FN#5			FN#6		FN#7
12 Months Ended September 30, 2016
BD MEDICAL
Medication Delivery Solutions (previously Medication and Procedural Solutions)		1,454		(92	)		—		198			(1	)		—			—		—		1,559
Medication Management Solutions		419		—			—		—			—			—			—		—		419
Diabetes Care		502		—			—		—			—			—			—		—		502
Pharmaceutical Systems		872		—			—		—			—			—			—		—		872
Respiratory Solutions		263		—			—		—			—			(263	)		—		—		—

TOTAL		3,510		(92	)		—		198			(1	)		(263	)		—		—		3,351

BD LIFE SCIENCES
Preanalytical Systems		694		—			—		—			—			—			—		—		694
Diagnostic Systems		701		—			—		—			—			—			—		—		701
Biosciences		685		—			—		—			—			—			—		—		685

TOTAL		2,080		—			—		—			—			—			—		—		2,080

BD INTERVENTIONAL
Surgery		—		87			—		143			(2	)		(10	)		—		—		218
Peripheral Intervention		—		5			—		466			(3	)		—			—		—		468
Urology and Critical Care		—		—			—		300			(1	)		—			—		—		299
Legacy Bard Product Groups
Vascular		—		—			355		(355	)		—			—			—		—		—
Urology		—		—			281		(281	)		—			—			—		—		—
Oncology		—		—			299		(299	)		—			—			—		—		—
Surgical Specialties		—		—			143		(143	)		—			—			—		—		—
Other		—		—			29		(29	)		—			—			—		—		—

TOTAL		—		92			1,107		(198	)		(5	)		(10	)		—		—		986

TOTAL INTERNATIONAL		5,590		—			1,107		—			(6	)		(274	)		—		—		6,418

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 3

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—INTERNATIONAL

(Unaudited; Amounts in millions)


	A		B			C		D			E			F			G		H		I=A+B+C+D +E+F+G+H		J		K=(I-J)/J		L=(I-J-M)/J		M
	BDX as Reported		BD Realign BUs			Bard as Reported		Bard Realign BUs			Bard Align Region Reporting			Divestiture Adjust			Gore Royalty Classification Adjust		Interco Adjust		Total NewCo as Adjusted		PY Comparable Period		Reported % Change		FXN % Change		FX Impact
			FN#1			FN#2		FN#3			FN#4			FN#5			FN#6		FN#7
12 Months Ended September 30, 2017
BD MEDICAL
Medication Delivery Solutions (previously Medication and Procedural Solutions)		1,529		(95	)		—		229			(1	)		—			—		—		1,663		1,559		6.7%		8.1%		(23	)
Medication Management Solutions		452		—			—		—			—			—			—		—		452		419		7.9%		10.6%		(11	)
Diabetes Care		510		—			—		—			—			—			—		—		510		502		1.6%		2.2%		(3	)
Pharmaceutical Systems		929		—			—		—			—			—			—		—		929		872		6.6%		7.3%		(6	)
Respiratory Solutions		—		—			—		—			—			—			—		—		—		—		NM		NM		—

TOTAL		3,419		(95	)		—		229			(1	)		—			—		—		3,553		3,351		6.0%		7.3%		(44	)

BD LIFE SCIENCES
Preanalytical Systems		730		—			—		—			—			—			—		—		730		694		5.2%		6.8%		(11	)
Diagnostic Systems		756		—			—		—			—			—			—		—		756		701		7.9%		8.8%		(6	)
Biosciences		684		—			—		—			—			—			—		—		684		685		-0.2%		0.8%		(7	)

TOTAL		2,170		—			—		—			—			—			—		—		2,170		2,080		4.3%		5.5%		(24	)

BD INTERVENTIONAL
Surgery		—		89			—		169			(2	)		(10	)		—		—		247		218		12.9%		16.5%		(8	)
Peripheral Intervention		—		6			—		518			(3	)		—			—		—		521		468		11.1%		12.6%		(7	)
Urology and Critical Care		—		—			—		321			—			—			—		—		320		299		7.0%		10.3%		(10	)
Legacy Bard Product Groups
Vascular		—		—			398		(398	)		—			—			—		—		—		—
Urology		—		—			305		(305	)		—			—			—		—		—		—
Oncology		—		—			338		(338	)		—			—			—		—		—		—
Surgical Specialties		—		—			169		(169	)		—			—			—		—		—		—
Other		—		—			27		(27	)		—			—			—		—		—		—

TOTAL		—		95			1,237		(229	)		(5	)		(10	)		—		—		1,088		986		10.3%		12.8%		(24	)

TOTAL INTERNATIONAL		5,589		—			1,237		—			(6	)		(10	)		—		—		6,811		6,418		6.1%		7.6%		(92	)

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 4

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—TOTAL

(Unaudited; Amounts in millions)


	A		B			C		D			E		F			G			H			I=A+B+C+D +E+F+G+H
	BDX as Reported		BD Realign BUs			Bard as Reported		Bard Realign BUs			Bard Align Region Reporting		Divestiture Adjust			Gore Royalty Classification Adjust			Interco Adjust			Total NewCo as Adjusted
			FN#1			FN#2		FN#3			FN#4		FN#5			FN#6			FN#7
12 Months Ended September 30, 2016
BD MEDICAL
Medication Delivery Solutions (previously Medication and Procedural Solutions)		3,413		(692	)		—		754			—		(19	)		—			(14	)		3,442
Medication Management Solutions		2,197		—			—		—			—		—			—			—			2,197
Diabetes Care		1,023		—			—		—			—		—			—			—			1,023
Pharmaceutical Systems		1,199		—			—		—			—		—			—			—			1,199
Respiratory Solutions		822		—			—		—			—		(822	)		—			—			—

TOTAL		8,654		(692	)		—		754			—		(842	)		—			(14	)		7,861

BD LIFE SCIENCES
Preanalytical Systems		1,409		—			—		—			—		—			—			—			1,409
Diagnostic Systems		1,301		—			—		—			—		—			—			—			1,301
Biosciences		1,119		—			—		—			—		—			—			—			1,119

TOTAL		3,829		—			—		—			—		—			—			—			3,829

BD INTERVENTIONAL
Surgery		—		672			—		641			—		(47	)		—			—			1,266
Peripheral Intervention		—		20			—		1,288			—		—			(158	)		—			1,150
Urology and Critical Care		—		—			—		935			—		—			—			—			935
Legacy Bard Product Groups
Vascular		—		—			992		(992	)		—		—			—			—			—
Urology		—		—			917		(917	)		—		—			—			—			—
Oncology		—		—			991		(991	)		—		—			—			—			—
Surgical Specialties		—		—			623		(623	)		—		—			—			—			—
Other		—		—			95		(95	)		—		—			—			—			—

TOTAL		—		692			3,618		(754	)		—		(47	)		(158	)		—			3,350

TOTAL WORLDWIDE		12,483		—			3,618		—			—		(889	)		(158	)		(14	)		15,040

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL

(Unaudited; Amounts in millions)


	A		B			C		D			E		F			G			H			I=A+B+C+D +E+F+G+H		J		K=(I-J)/J		L=(I-J-M)/J		M
	BDX as Reported		BD Realign BUs			Bard as Reported		Bard Realign BUs			Bard Align Region Reporting		Divestiture Adjust			Gore Royalty Classification Adjust			Interco Adjust			Total NewCo as Adjusted		PY Comparable Period		Reported % Change		FXN % Change		FX Impact
			FN#1			FN#2		FN#3			FN#4		FN#5			FN#6			FN#7
12 Months Ended September 30, 2017
BD MEDICAL
Medication Delivery Solutions (previously Medication and Procedural Solutions)		3,497		(685	)		—		800			—		—			—			(14	)		3,598		3,442		4.5%		5.2%		(23	)
Medication Management Solutions		2,295		—			—		—			—		—			—			—			2,295		2,197		4.4%		4.9%		(11	)
Diabetes Care		1,056		—			—		—			—		—			—			—			1,056		1,023		3.3%		3.6%		(3	)
Pharmaceutical Systems		1,256		—			—		—			—		—			—			—			1,256		1,199		4.8%		5.3%		(6	)
Respiratory Solutions		—		—			—		—			—		—			—			—			—		—		NM		NM		—

TOTAL		8,105		(685	)		—		800			—		—			—			(14	)		8,205		7,861		4.4%		4.9%		(44	)

BD LIFE SCIENCES
Preanalytical Systems		1,471		—			—		—			—		—			—			—			1,471		1,409		4.4%		5.2%		(11	)
Diagnostic Systems		1,378		—			—		—			—		—			—			—			1,378		1,301		5.9%		6.4%		(6	)
Biosciences		1,139		—			—		—			—		—			—			—			1,139		1,119		1.8%		2.4%		(7	)

TOTAL		3,988		—			—		—			—		—			—			—			3,988		3,829		4.2%		4.8%		(24	)

BD INTERVENTIONAL
Surgery		—		666			—		680			—		(48	)		—			—			1,298		1,266		2.6%		3.2%		(8	)
Peripheral Intervention		—		19			—		1,393			—		—			(173	)		—			1,239		1,150		7.7%		8.3%		(7	)
Urology and Critical Care		—		—			—		1,002			—		—			—			—			1,002		935		7.2%		8.2%		(10	)
Legacy Bard Product Groups
Vascular		—		—			1,085		(1,085	)		—		—			—			—			—		—
Urology		—		—			980		(980	)		—		—			—			—			—		—
Oncology		—		—			1,052		(1,052	)		—		—			—			—			—		—
Surgical Specialties		—		—			660		(660	)		—		—			—			—			—		—
Other		—		—			98		(98	)		—		—			—			—			—		—

TOTAL		—		685			3,875		(800	)		—		(48	)		(173	)		—			3,539		3,350		5.6%		6.4%		(24	)

TOTAL WORLDWIDE		12,093		—			3,875		—			—		(48	)		(173	)		(14	)		15,732		15,040		4.6%		5.2%		(92	)

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—EMERGING & DEVELOPED MARKETS, CHINA

(Unaudited; Amounts in millions)


	A		B		C		D		E			F			G			H			I=A+B+C+D +E+F+G+H
	BDX as Reported		BD Realign BUs		Bard as Reported		Bard Realign BUs		Bard Align Region Reporting			Divestiture Adjust			Gore Royalty Classification Adjust			Interco Adjust			Total NewCo as Adjusted
			FN#1		FN#2		FN#3		FN#4			FN#5			FN#6			FN#7
12 Months Ended September 30, 2016
EMERGING MARKETS		1,904		—		363		—		(29	)		(107	)		—			—			2,132
DEVELOPED MARKETS		10,579		—		3,254		—		29			(782	)		(158	)		(14	)		12,908
CHINA		663		—		215		—		—			(23	)		—			—			855

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 7

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE—EMERGING & DEVELOPED MARKETS, CHINA

(Unaudited; Amounts in millions)

I=A+B+C+D

+E+F+G+H

K=(I-J)/J

L=(I-J-M)/J

BDX as

Reported

BD
Realign
BUs

Bard as
Reported

Bard
Realign
BUs

Bard Align
Region
Reporting

Divestiture
Adjust

Gore Royalty
Classification
Adjust

Interco
Adjust

Total NewCo

as Adjusted

Comparable

Period

Reported %
Change

FXN %
Change

FX
Impact

FN#1

FN#2

FN#3

FN#4

FN#5

FN#6

FN#7

12 Months Ended September 30, 2017

EMERGING MARKETS

1,953

—

434

—

(33

)

—

2,352

2,132

10.3

12.0

(36

)

DEVELOPED MARKETS

10,140

—

3,442

—

(46

)

(173

)

(14

)

13,380

12,908

3.7

4.1

(56

)

CHINA

686

—

254

—

)

—

940

855

9.9

14.5

(39

)

Footnote Explanations

1	Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see Item 2.02 of the 8-K.

2	Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD’s fiscal year and quarterly reporting cycle.

4	Represents re-alignment of Bard country reporting to align to BD’s existing presentation.

5	Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira^® product line of tunneled home drainage catheters and accessories.

6	Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.

7	Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

Page 8